Taysha Gene Therapies (TSHA) Misses Q4 EPS by 7c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q4 EPS of ($1.32), $0.07 worse than the analyst estimate of ($1.25).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• Bimergen Energy Corporation (BESS) Reports Q2 EPS of $0.22